HELIXATE FS, KOGENATE, KOGENATE FS Drug Profile

Summary for Tradename: HELIXATE FS, KOGENATE, KOGENATE FS

High Confidence Patents:	3
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HELIXATE FS, KOGENATE, KOGENATE FS Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HELIXATE FS, KOGENATE, KOGENATE FS Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2017-05-09	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2018-05-08	DrugPatentWatch analysis and company disclosures
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2029-08-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HELIXATE FS, KOGENATE, KOGENATE FS Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2019-11-23	Patent claims search
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2019-08-17	Patent claims search
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2019-10-18	Patent claims search
Bayer Healthcare Llc	HELIXATE FS, KOGENATE, KOGENATE FS	antihemophilic factor (recombinant)	For Injection	103332		2034-04-23	Patent claims search

International Patents for HELIXATE FS, KOGENATE, KOGENATE FS

Country	Patent Number	Estimated Expiration
Spain	2930143
South Korea	101468345
Croatia	P20180481
China	105753968
France	19C1031
Portugal	2363414

Supplementary Protection Certificates for HELIXATE FS, KOGENATE, KOGENATE FS

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
399 50013-2019	Slovakia		PRODUCT NAME: DAMOKTOKOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/18/1324/001 - EU/1/18/1324/005 20181126
122019000039	Germany		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; REGISTRATION NO/DATE: EU/1/18/1324 20181122
SPC/GB19/034	United Kingdom		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; REGISTERED: UK EU/1/18/1324 20181122; UK PLGB 00010/0682 20181122; UK PLGB 00010/0683 20181122; UK PLGB 00010/0684 20181122; UK PLGB 00010/0685 20181122; UK PLGB 00010/0686 20181122
C201930033	Spain		PRODUCT NAME: JIVI - DAMOCTOCOG ALFA PEGOL; NATIONAL AUTHORISATION NUMBER: EU/1/18/1324; DATE OF AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1324; DATE OF FIRST AUTHORISATION IN EEA: 20181122
1990029-9	Sweden		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; REG. NO/DATE: EU/1/18/1324 20181126
C 2019 025	Romania		PRODUCT NAME: DAMOCTOCOG ALFA PEGOL; NATIONAL AUTHORISATION NUMBER: EU/1/18/1324; DATE OF NATIONAL AUTHORISATION: 20181122; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1324; DATE OF FIRST AUTHORISATION IN EEA: 20181122

HELIXATE FS, KOGENATE, KOGENATE FS: Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What are these products, and what markets do they define?

HELIXATE FS and KOGENATE (including KOGENATE FS) are plasma-derived/engineered human coagulation factor VIII products used for hemophilia A care. They sit in the core “factor VIII replacement” market where pricing, payer coverage, and competitive substitution drive revenue outcomes. Market dynamics also hinge on prophylaxis adoption, shared-care guidelines, and the shift toward longer-acting factor VIII and non-factor replacement therapies.

Portfolio mapping

• KOGENATE / KOGENATE FS: factor VIII brand portfolio (FS formulation indicates a formulation variant used for administration profile and handling).
• HELIXATE FS: factor VIII brand with “FS” formulation variant used for hemophilia A replacement.

Competitive set (commercially relevant)

• Other recombinant and recombinant-like factor VIII products in the standard-acting segment.
• Longer-acting factor VIII products and non-factor options (e.g., emicizumab and other non-factor agents) that reduce dosing frequency and can reallocate payer spend away from standard factor VIII.

How do market dynamics affect HELIXATE FS and KOGENATE/KOGENATE FS revenue?

Revenue trajectories in hemophilia A factor VIII are shaped by four repeatable dynamics.

1) Physician preference and substitution constraints

• Payers often require step therapy or formulary placement. In practice, switching within factor VIII brands can occur when lower net price or preferred contracting is available.
• Patient continuity can slow interchange, so revenue risk is concentrated in formulary cycles, tender wins, and lifecycle changes.

2) Payer pricing pressure and rebate intensity

• Standard-acting factor VIII faces ongoing pressure as biosimilar-like alternatives and competitors with aggressive contracting enter or expand coverage.
• Net price compresses faster than list price in jurisdictions with stronger pharmacy benefit controls or centralized purchasing.

3) Shift to non-factor and longer-acting therapies

• Emicizumab-type and longer-acting factor VIII regimens reduce infusion frequency and can convert patients off standard factor VIII.
• The effect is not uniform: patients with specific bleeding patterns, breakthrough needs, inhibitors status, and adherence constraints can remain on factor VIII longer. That keeps baseline demand, but growth rates typically slow.

4) Volume growth is real, but growth rates are constrained

• Hemophilia A prevalence and prophylaxis penetration support baseline volume growth.
• Growth slows when eligible patients migrate to longer-acting or non-factor regimens, and when payers restrict switching from preferred non-factor or longer-acting products.

What is the financial trajectory implied by the brands’ commercial lifecycle?

For branded factor VIII products, the financial shape typically follows a late-stage pattern:

• Early growth phase: new patient starts and formulary inclusion.
• Mid-cycle stability: contract renewals sustain volume.
• Late-stage pressure: competitor wins, contracting compression, and conversion to longer-acting/non-factor reshape revenue down and flatten new starts.

HELIXATE FS and KOGENATE/KOGENATE FS are long-standing brands. As competitors added longer-acting and non-factor options, the commercial trajectory for standard-acting factor VIII generally shifts from growth to maintenance, with revenue increasingly tied to payer contracting and patient retention.

What do you need to model for cash flow, pricing, and net revenue?

A practical financial model for these products should treat revenue as a function of (1) treated population and dosing intensity, (2) net price after rebates and discounts, and (3) conversion away from standard factor VIII.

Core drivers to plug into the model

• Unit demand: number of patients on factor VIII and annual consumption (IU per patient per year).
• Net price: list price less rebates, discounts, and payer-specific concessions.
• Mix: shift within factor VIII from one formulation to another (FS vs non-FS), and shift between standard and longer-acting/non-factor.
• Persistence: rate of patient switching from factor VIII to non-factor or longer-acting.
• Geography: US vs ex-US pricing and contracting differences; tender-based markets can cause sharp quarters-to-quarters variability.

Key commercial sensitivities (directional)

Lever	Revenue impact direction	Why it matters for HELIXATE FS/KOGENATE/KOGENATE FS
Faster conversion to non-factor (emicizumab-type)	Down	Reduces new factor VIII starts and can shorten persistence
Increased payer preference for competitors	Down	Net price drops via contracting and formulary tiering
Reduced net price (higher rebates/discounts)	Down	Often compresses gross-to-net conversion even if unit volume stays
Improved contracting stability	Up	Sustains net pricing and persistence
Higher prophylaxis adoption (in under-treated markets)	Up	Raises baseline treated population and consumption

How do these brands compare on market exposure and competitive risk?

The market exposure is structurally similar across HELIXATE FS and KOGENATE/KOGENATE FS because:

• They both compete in standard-acting hemophilia A replacement.
• Both face the same payer ecosystem pressures: formulary control, rebate intensity, and step therapy requirements.

The difference comes from localized contracting and historical market penetration in specific geographies and payer channels. Without brand-level segment disclosures in available public filings for this request, the correct actionable inference is to treat both brands as part of the same revenue engine category: standard factor VIII in a late-cycle compression environment.

What does the trajectory imply for future growth and downside?

Base-case financial expectation

• Volume: modest growth supported by baseline prophylaxis adoption.
• Net price: downward drift driven by competitive contracting.
• Net revenue: flattish to declining in rate terms as longer-acting/non-factor expand.

Downside scenarios

• Larger-than-expected formulary shifts away from standard factor VIII in key payers.
• Accelerated patient conversion to non-factor/longer-acting therapies.
• Further net price compression from competitor aggressive contracting.

Upside scenarios

• Contract wins that lock in net price for longer.
• Stable persistence with fewer conversions than expected.
• Stronger reimbursement access in markets still scaling prophylaxis.

What are the actionable market conclusions for investors and R&D planners?

1. This is a late-cycle standard-acting factor VIII exposure. Market growth exists, but it is increasingly offset by payer-driven net price compression and patient conversion to non-factor and longer-acting regimens.
2. FS variants reduce administration friction but do not change the therapeutic substitution direction. They can stabilize handling and payer preferences, but they do not reverse the class-level shift.
3. Financial trajectory will track net price and persistence more than pure prevalence. The durable question is how quickly treated patients rotate to newer regimens through payer and physician switching.

Key Takeaways

• HELIXATE FS and KOGENATE/KOGENATE FS define standard-acting factor VIII exposure in hemophilia A.
• Market dynamics pressure net revenue through payer contracting, rebate intensity, and substitution pressure from longer-acting and non-factor therapies.
• The likely financial trajectory is stabilization to gradual decline in growth rate, driven by net price drift and patient conversion, with volume providing only partial offset.
• For modeling and decision-making, persistence and net price are the critical sensitivities; unit demand growth alone does not determine direction.

FAQs

1) What primarily drives revenue changes for standard factor VIII brands like HELIXATE FS and KOGENATE FS?
Net price (payer contracting and rebates) and persistence (conversion to longer-acting or non-factor therapies).

2) Does the “FS” formulation typically change market substitution dynamics?
It can affect administration and payer preferences, but substitution from standard-acting factor VIII to newer regimens is mainly governed by regimen-level value and payer policy.

3) Are unit volume trends enough to protect financial performance?
No. Baseline prophylaxis expansion can be offset by net price compression and faster conversion out of standard-acting factor VIII.

4) Where does quarter-to-quarter volatility usually come from?
Contracting cycles, formulary tier changes, and shifts in treated-patient mix by geography and payer channel.

5) What is the highest-leverage variable for forecasting cash flow?
Persistence: the speed at which patients move from factor VIII replacement to longer-acting factor VIII or non-factor regimens.

---

References

[1] U.S. Food and Drug Administration. Label information for factor VIII products (HELIXATE FS, KOGENATE, KOGENATE FS). (Access via FDA Drugs@FDA).